Dates

Quote




Next year and across all field divisions. HSBS cv resp Dia. All thrown into pool and then reduction from that. It will not be just division focused. Some will transfer and products will be realigned. Ah could move to bi as some bi leave.
 



Next year? CBD’s have been sharing the next couple of weeks will be informative of all of our fates. It goes in to effect the beginning of the year but no way they are waiting that long to trim the fat. 3 areas down to 2, 20% reduction in CBD’s and appropriate size for future success with DM’s and reps-20-40% depending on location.
 









anonymous said:
Next year? CBD’s have been sharing the next couple of weeks will be informative of all of our fates. It goes in to effect the beginning of the year but no way they are waiting that long to trim the fat. 3 areas down to 2, 20% reduction in CBD’s and appropriate size for future success with DM’s and reps-20-40% depending on location.
Click to expand...

3 areas down to 2 makes sense. 1 east and 1 west. Let the other AVP find something else to do. Reduce CBD role by 3-4 people.

Too many people selling not enough product. We can accomplish the same results with less.
 



anonymous said:
3 areas down to 2 makes sense. 1 east and 1 west. Let the other AVP find something else to do. Reduce CBD role by 3-4 people.

Too many people selling not enough product. We can accomplish the same results with less.
Click to expand...
Agree. People forget that 50% of all diabetes profits go to Lilly. The type 2 market is extremely competitive and Jardiance is doing well but certainly not growing as expected. The entire SGLT2 market is flat. Nobody's fault really, just too many drugs chasing a limited # of patients.
 



anonymous said:
3 areas down to 2 makes sense. 1 east and 1 west. Let the other AVP find something else to do. Reduce CBD role by 3-4 people.

Too many people selling not enough product. We can accomplish the same results with less.
Click to expand...
Agree. People forget that 50% of all diabetes profits go to Lilly. The type 2 market is extremely competitive and Jardiance is doing well but certainly not growing as expected. The entire SGLT2 market is flat. Nobody's fault really, just too many drugs chasing a limited # of patients.
 






anonymous said:
Next year? CBD’s have been sharing the next couple of weeks will be informative of all of our fates. It goes in to effect the beginning of the year but no way they are waiting that long to trim the fat. 3 areas down to 2, 20% reduction in CBD’s and appropriate size for future success with DM’s and reps-20-40% depending on location.
Click to expand...

I keep hearing it’s just CV.
 






anonymous said:
Agree. People forget that 50% of all diabetes profits go to Lilly. The type 2 market is extremely competitive and Jardiance is doing well but certainly not growing as expected. The entire SGLT2 market is flat. Nobody's fault really, just too many drugs chasing a limited # of patients.
Click to expand...
What a joke. 50% for doing NOTHING.
 



And that is why the change in headcount is needed. Bad decision making from above and they keep happening... the only team that can make it happen is diabetes... Sorry it’s not just CV it’s everyone and makes sense some of the best reps are on respiratoryz. Your crazy if you think we can keep low net sales and keep everyone. From what i am hearing looking like performance based and geographicaly located needs and rep location
 



Top Bottom
Back
Quote